Inotiv, Inc. (NASDAQ:NOTV) saw an uptick in trading volume on Thursday . 8,766 shares traded hands during trading, a decline of 93% from the previous session’s volume of 120,831 shares.The stock last traded at $33.92 and had previously closed at $34.11.
A number of brokerages recently weighed in on NOTV. Colliers Securities reaffirmed a “buy” rating on shares of Inotiv in a research report on Wednesday. Craig Hallum began coverage on shares of Inotiv in a research report on Monday, September 20th. They set a “buy” rating and a $45.00 price target for the company.
The business has a 50-day simple moving average of $29.31. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.02 and a quick ratio of 1.00. The firm has a market capitalization of $546.20 million, a PE ratio of -85.80 and a beta of 2.09.
A number of hedge funds have recently modified their holdings of the business. Next Century Growth Investors LLC lifted its holdings in Inotiv by 16.9% in the 2nd quarter. Next Century Growth Investors LLC now owns 730,507 shares of the company’s stock worth $19,489,000 after buying an additional 105,491 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Inotiv in the 1st quarter valued at about $13,623,000. BlackRock Inc. raised its stake in shares of Inotiv by 1,797.6% in the 2nd quarter. BlackRock Inc. now owns 635,747 shares of the company’s stock valued at $16,963,000 after purchasing an additional 602,245 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Inotiv by 46.0% in the 2nd quarter. Vanguard Group Inc. now owns 544,270 shares of the company’s stock valued at $14,521,000 after purchasing an additional 171,456 shares in the last quarter. Finally, Ophir Asset Management Pty Ltd acquired a new stake in shares of Inotiv in the 2nd quarter valued at about $13,126,000. Hedge funds and other institutional investors own 43.02% of the company’s stock.
About Inotiv (NASDAQ:NOTV)
Inotiv, Inc operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing.
Further Reading: What is channel trading?
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.